Comparative efficiency of feline immunodeficiency virus infection by DNA inoculation.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Comparative efficiency of feline immunodeficiency virus infection by DNA inoculation.

AIDS Res Hum Retroviruses. 1997 Mar 20;13(5):405-12. Unique Identifier : AIDSLINE GENBANK/M25381
Rigby MA; Hosie MJ; Willett BJ; Mackay N; McDonald M; Cannon C; Dunsford T; Jarrett O; Neil JC; Department of Veterinary Pathology, University of Glasgow; Veterinary School, UK.

Abstract: Direct inoculation of genetic material in DNA form is a novel approach to vaccination that has proved efficacious for a number of viral agents. We are interested in the potential of this approach for the delivery of vaccines based on attenuated or replication-defective retroviruses. Toward this goal, we tested the effect of intramuscular inoculation of a plasmid containing the entire genome of feline immunodeficiency virus (FIV-Petaluma, F14 clone). DNA delivery was compared with intramuscular or intraperitoneal inoculation of virus reconstituted from the same molecular clone. The outcome was monitored by serological analysis and quantitative virus load determination over a 31-week period. DNA inoculation was found to be a reliable means of infection, although seroconversion and the rise in PBMC virus load were delayed relative to intramuscular or intraperitoneal inoculation of virus. At 31 weeks, similar levels of proviral DNA were detected in central lymphoid tissue of all infected animals. In conclusion, DNA inoculation of proviral DNA will be of use as a novel method of cell-free virus challenge and may have further potential for the delivery of lentiviral vaccines.

Keywords: Animal Antibodies, Viral/BLOOD Cats Comparative Study DNA, Viral/ANALYSIS/BLOOD Gene Products, gag Immunodeficiency Virus, Feline/*IMMUNOLOGY/ISOLATION & PURIF Lentivirus Infections/IMMUNOLOGY/*VIROLOGY Leukocytes, Mononuclear Lymph Nodes/VIROLOGY Molecular Sequence Data Proviruses Support, Non-U.S. Gov't Vaccines, DNA/*ADMINISTRATION & DOSAGE Viral Load Viral Vaccines/*ADMINISTRATION & DOSAGE JOURNAL ARTICLE
970830
M9780771

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .